Bisphosphonates are widely used drugs for the management of osteoporosis. Intravenous (IV) zoledronic acid (ZA) is frequently prescribed in cases of oral bisphosphonate intolerance or non-compliance. Well-known immediate ZA side effects include flu-like symptoms such as nausea, myalgias, bone and joint pains, and fever. Here we report a case of a rare side effect of acute anterior uveitis following initial dosing of ZA in a 71-year-old female with osteoporosis who had been vitamin D deficient a couple of months earlier. She presented with headache, bilateral eye redness, and pain post ZA infusion. Findings of diffuse conjunctival injection, and flare with cells in the anterior chamber were suggestive of anterior uveitis. Her symptoms resolved with prednisolone eye drops in three weeks. Ocular inflammation is a rare but serious side effect of this commonly administered drug. Optimizing vitamin D levels prior to treatment may help to prevent this condition. Clinicians should be aware of the rare occurrence of post-ZA ocular inflammation. Early recognition and prompt treatment are essential.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484521 | PMC |
| http://dx.doi.org/10.7759/cureus.43162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Hypercalcemia Following Hip Joint Implantation of Calcium Sulfate Antibiotic Beads: Case Series and Review of Literature.
J Community Hosp Intern Med Perspect
January 2025
Division of Hospital Medicine, Johns Hopkins Community Physicians, Johns Hopkins Medicine, Baltimore, MD, USA.
Purpose: The diagnosis and management of hypercalcemia in hospitalized patients can be challenging. Hypercalcemia is often associated with significant morbidity and end-organ damage which may delay a patient's recovery.
Methods: We report a case series of three patients who underwent orthopedic procedures with intraoperative placement of vancomycin-loaded calcium sulfate beads.
Chapter 12: PREPARATION FOR PARATHYROID SURGERY.
Ann Endocrinol (Paris)
January 2025
Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, 94 275 Le Kremlin Bicêtre, France. Electronic address:
Preoperative treatment of PHPT aims to 1) manage severe and/or symptomatic hypercalcemia and 2) prevent postoperative hypocalcemia. Severe hypercalcemia, defined as a blood calcium level ≥ 3.5 mmol/L, requires admission to hospital in a conventional or critical care unit, depending on clinical symptoms and comorbidities.
View Article and Find Full Text PDFCraniofacial Effects of Zoledronic Acid on the Osteogenesis Imperfecta Mouse (-/-) Model of Severe Osteogenesis Imperfecta.
Biomedicines
November 2024
Pole of Morphology, Institute of Experimental and Clinical Research, UCLouvain, 1200 Brussels, Belgium.
Osteogenesis imperfecta (OI) is a rare genetic disorder affecting mainly type I collagen, which leads to bone fragility and deformities. OI patients also present craniofacial abnormalities such as macrocephaly and malocclusion. Recently, craniofacial dysmorphism was highlighted in the osteogenesis imperfecta mouse (oim), a validated model of the most severe form of OI.
View Article and Find Full Text PDFArticle Synopsis
- Relapsing polychondritis (RP) is a rare autoimmune disorder that causes recurring inflammation in cartilaginous tissues, affecting areas like the ears, nose, and joints.
- A 68-year-old woman without prior health issues showed symptoms like hoarseness, polyarthritis, and nasal/ear involvement, leading to her RP diagnosis using the Modified McAdam criteria.
- She was treated with intravenous cyclophosphamide and oral prednisolone, which improved her condition, while osteoporosis was treated with zoledronic acid, highlighting RP's role in patient assessments involving similar symptoms.
Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study.
BMJ Open Ophthalmol
December 2024
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
Article Synopsis
- The study aimed to evaluate the feasibility of using zoledronic acid (ZA) as a supplementary treatment for neovascular age-related macular degeneration (nAMD) in a randomized controlled trial.
- A total of 40 nAMD patients were split into two groups, with one receiving ZA and the other a placebo, and the primary focus was on changes in visual acuity after treatment.
- Results showed that the group receiving ZA had improved visual acuity compared to the placebo group, suggesting potential benefits that warrant further exploration, although the small sample size limits the strength of these findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!